US high court seeks government's views on generic drug pre-emption case
This article was originally published in Scrip
Executive Summary
The US Supreme Court is asking for the Obama Administration's views on whether a generic drug company can face state-based, failure-to-warn claims for product labelling that mirrors the reference listed drug.